DCGI gives emergency use nod to Moderna’s vaccine

DCGI gives emergency use nod to Moderna’s vaccine

The Drugs Controller General of India (DCGI) gives emergency use nod to Moderna’s COVID-19 vaccine. Importing of the vaccines from the US will be facilitated by Indian drug pharma Cipla, under licence for restricted use by DCGI. However, at present, Cipla is allowed to import only those doses that Moderna has committed to donate to India.

In May, the Biden administration announced the donation of coronavirus vaccines through the COVAX scheme for distribution in low-income and developing countries, including India. The imported jabs are part of the donation which the US government promised. The US is expected to send a total of 20 million doses of the Moderna vaccine to these countries.
According to the World Health Organisation, the Moderna vaccine has shown to have an efficacy of approximately 94.1 per cent in protecting against Covid-19, starting 14 days after the first dose. The WHO adds that based on evidence collected so far, the new variants of SARS-CoV-2, including the B.1.1.7 and the 501Y.V2, do not alter the effectiveness of the Moderna mRNA vaccine.
Moderna’s vaccine becomes the fourth to get emergency authorisation in the country after Serum Institute’s Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik V.